UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

The Lancet (British edition), 2000-11, Vol.356 (9243), p.1728-1733

2000

Volltextzugriff (PDF)

Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells

European journal of clinical investigation, 2007-01, Vol.37 (1), p.73-82

2007

Volltextzugriff (PDF)

Antisense molecules for targeted cancer therapy

Critical reviews in oncology/hematology, 2006-07, Vol.59 (1), p.65-73

2006

Volltextzugriff (PDF)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

British journal of cancer, 2009-06, Vol.100 (11), p.1739-1745

2009

Volltextzugriff (PDF)

Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound

European journal of clinical investigation, 2009-05, Vol.39 (5), p.384-394

2009

Volltextzugriff (PDF)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

British journal of cancer, 2009-06, Vol.100 (11), p.1739-1745

2009

Volltextzugriff (PDF)

1198TiP A phase Ib/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer

Annals of oncology, 2022-09, Vol.33, p.S1096

2022

Volltextzugriff (PDF)

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002

British journal of dermatology (1951), 2009-05, Vol.160 (5), p.955-964

2009

Volltextzugriff (PDF)

Innovation in oncology clinical trial design

Cancer treatment reviews, 2019-03, Vol.74, p.15-20

2019

Volltextzugriff (PDF)

Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma

Digestive and liver disease, 2009-12, Vol.41 (12), p.902-906

2009

Volltextzugriff (PDF)

SO-5 Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study

Annals of oncology, 2023-06, Vol.34, p.S163-S163

2023

Volltextzugriff (PDF)

A clinical trial on absorption and N-acetylation of oral and rectal mesalazine

European journal of clinical investigation, 2007-07, Vol.37 (7), p.558-565

2007

Volltextzugriff (PDF)

Erythropoietin receptor expression in human melanoma cells

Melanoma research, 2000-10, Vol.10 (5), p.421-426

2000

Volltextzugriff (PDF)

Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells

British journal of cancer, 2003-10, Vol.89 (7), p.1352-1357

2003

Volltextzugriff (PDF)

52P Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA)

Annals of oncology, 2021-09, Vol.32, p.S378-S379

2021

Volltextzugriff (PDF)

51P Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)

Annals of oncology, 2021-09, Vol.32, p.S378-S378

2021

Volltextzugriff (PDF)

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

Transplantation, 2007-02, Vol.83 (4), p.425-432

2007

Volltextzugriff (PDF)

PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS)

Value in health, 2018-10, Vol.21, p.S383-S384

2018

Volltextzugriff (PDF)

POSA354 Patient-Reported Outcomes in Futibatinib-Treated Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusions/Rearrangements: Results from the Foenix-CCA2 Study

Value in health, 2022-01, Vol.25 (1), p.S218-S219

2022

Volltextzugriff (PDF)

A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells

Molecular medicine (Cambridge, Mass.), 2000-08, Vol.6 (8), p.693-704

2000

Volltextzugriff (PDF)

A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27, p.vi441-vi441

2016

Volltextzugriff (PDF)

Strategies for designing clinical trials for oligonucleotide therapeutics

Drug Discovery Today, 2004-11, Vol.9 (21), p.918-923

Wacheck, Volker

2004

Volltextzugriff (PDF)

Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells

Journal of investigative dermatology, 2000-05, Vol.114 (5), p.935-940

2000

Volltextzugriff (PDF)

Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells

Cellular signalling, 2004-11, Vol.16 (11), p.1319-1327

2004

Volltextzugriff (PDF)

Compact, broad-bandwidth fiber laser for sub-2-µm axial resolution optical coherence tomography in the 1300-nm wavelength region

Optics letters, 2003-05, Vol.28 (9), p.707

2003

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(56)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Humans
(24)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Female
(12)
Animals
(8)
Cell Line, Tumor
(8)
Medicine, Research & Experimental
(8)
Oncology
(8)
Research & Experimental Medicine
(8)
Male
(7)
Mice
(7)
Apoptosis
(6)
Middle Aged
(6)
Proto-Oncogene Proteins C-Bcl-2 - Genetics
(6)
Transfection
(6)
Adult
(5)
Apoptosis - Drug Effects
(5)
Blotting, Western
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells

Antisense molecules for targeted cancer therapy

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

1198TiP A phase Ib/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002

Innovation in oncology clinical trial design

Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma

SO-5 Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study

A clinical trial on absorption and N-acetylation of oral and rectal mesalazine

Erythropoietin receptor expression in human melanoma cells

Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells

52P Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA)

51P Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS)

POSA354 Patient-Reported Outcomes in Futibatinib-Treated Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusions/Rearrangements: Results from the Foenix-CCA2 Study

A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells

A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)

Strategies for designing clinical trials for oligonucleotide therapeutics

Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells

Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells

Compact, broad-bandwidth fiber laser for sub-2-µm axial resolution optical coherence tomography in the 1300-nm wavelength region

Suchergebnisse filtern